Stay updated with breaking news from Hepatitis D. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
World Hepatitis Day is an opportunity to remind people of the impact of viral hepatitis and to offer information that can help prevent, diagnose, and treat these diseases, said one expert.
There is no approved treatment for chronic hepatitis D virus infection in the United States, but recent phase 3 trial results showed encouraging safety and efficacy associated with bulevirtide.
Bulevirtide, an investigational, first-in-class hepatitis delta virus entry-inhibitor, significantly reduced viral load and normalized liver enzymes in patients.
Contrary to previous assumptions, hepatitis D virus-like agents seem to be active in a range of different animal species, from fish all the way to termites.
In 2020, bulevirtide (BLV) was conditionally approved for treating chronic hepatitis delta (CHD), an inflammation of the liver caused by hepatitis D virus (HDV).